Anti-CD28 compositions
Provided herein are novel anti-CD28×anti-B7H3 (also referred to as “αCD28×αB7H3”) heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers. Subject αCD28×αB7H3 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and targeting to B7H3 on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful for enhancing anti-tumor activity when used in combination with other anti-cancer therapies.
1. A heterodimeric antibody that binds to human CD28 and human B7H3 comprising:
a) a first monomer comprising the amino acid sequence of SEQ ID NO:1019;
b) a second monomer comprising the amino acid sequence of SEQ ID NO:1020; and
c) a light chain comprising the amino acid sequence of SEQ ID NO:1021.
2. A nucleic acid composition comprising:
a) a first nucleic acid encoding the amino acid sequence of SEQ ID NO:1019;
b) a second nucleic acid encoding the amino acid sequence of SEQ ID NO:1020; and
c) a third nucleic acid encoding the amino acid sequence of SEQ ID NO:1021.
3. An expression vector composition comprising:
a) a first expression vector comprising a first nucleic acid encoding the amino acid sequence of SEQ ID NO:1019;
b) a second expression vector comprising a second nucleic acid encoding the amino acid sequence of SEQ ID NO:1020; and
c) a third expression vector comprising a third nucleic acid encoding the amino acid sequence of SEQ ID NO:1021.
4. A host cell comprising the expression vector composition of claim 3 .
5. A method of making a heterodimeric antibody that binds to human CD28 and human B7H3 comprising culturing the host cell of claim 4 under conditions whereby said heterodimeric antibody is expressed and recovering said heterodimeric antibody.